MANUSHAK AVANESYAN: Open Payments
NPI 1568120608 · NORTH LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,533 in 68 payments from 14 companies in 2025. Trend: 2023 $1,335 · 2024 $1,243 · 2025 $1,533
Food & beverage: $1,449Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 21 | $488 |
| ABBVIE INC. | 15 | $301 |
| Ardelyx, Inc. | 2 | $146 |
| Celltrion USA Inc. | 5 | $104 |
| GENZYME CORPORATION | 6 | $100 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $99 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Novo Nordisk Inc | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| PFIZER INC. | 2 | $35 |
Products named: TREMFYA, DUPIXENT, IBSRELA, VEGZELMA, SKYRIZI, XIFAXAN, IQIRVO, CREON.
Industry payments across NV — which companies pay providers there.
